Fas ligand or FasL (CD178 or CD95L) is a homotrimeric human type II transmembrane protein. The Fas ligand gene (FASLG) on chromosome 1q24.3 encodes the Fas ligand protein. Cytotoxic T lymphocytes express FasL on their surfaces that belong to the TNF family of proteins. By binding to its receptors, FasL induces apoptosis in cells. A matrix metalloproteinase MMP-7 cleaves membrane-bound FasL and generates a soluble FasL.
Fas ligand (FASLG) is a homotrimeric human type II transmembrane protein that binds to the Fas receptor (FasR). The Fas ligand gene (FASLG) on chromosome 1q24.3 encodes the Fas ligand protein. Cytotoxic T lymphocytes express FasL on their surfaces that belong to the TNF family of proteins. By binding to its receptors, FasL induces apoptosis in cells. A matrix metalloproteinase MMP-7 cleaves membrane-bound FasL and generates a soluble FasL.Fas ligand (FasL) is a type II transmembrane protein that belongs to the tumor necrosis factor (TNF) receptor superfamily. FasL interacts with its receptors, FasR and CD95, which belong to the death receptor family. Upon binding of FasL to its receptors on the surface of a cell, FasR trimerizes and initiates apoptosis via downstream signalling molecules including caspases-8 and caspases-9. A soluble form of FasL has been recently identified, generated by proteolytic cleavage at the membrane.
Fas ligand (FasL) is an important regulatory molecule that plays an essential role in immune system. FasL is a member of the tumor necrosis factor (TNF) family of proteins. TNF family members include tumor necrosis factors (TNFs), lymphotoxin-alpha (LTalpha), LTbeta, LTgamma, CD40 ligand (CD40L), OX40 ligand (OX40L), Fas associated death domain protein (FADD), CD30 ligand, CD27 ligand and many others.
A pharmacokinetic study provides the basis for determining drug exposures in the body over time. Pharmacokinetics is the quantitative study of how medications are absorbed and eliminated from the body. PK parameters include plasma concentration, area under curve, clearance, volume of distribution, apparent distribution volume (Vd) and maximum plasma concentration. Pharmacokinetic studies provide the basis for determining drug exposures in the body over time. Pharmacokinetic properties include: absorption, distribution and excretion (ADME) processes of drugs. Pharmacokinetics is useful in selecting a suitable dose for an individual patient in clinical trials by knowing the pharmacokinetics of a drug and understanding how it might be modified during treatment.
The third part of the pharmacokinetic model is the elimination process, which shows how much drug is diverted to other processes as opposed to being excreted in urine and sweat. Drugs may also be broken down chemically in the body into metabolites, which are substances that are not eliminated directly but are instead converted by the body into less toxic compounds. A pharmacokinetic study provides the basis for determining drug exposures in the body over time. PK research are used in the evaluation of the absorption, distribution, metabolism, and excretion (ADME) processes of drugs.
A PK study provides the basis for determining drug exposures in the body over time. PK parameters are used in the evaluation of the absorption, distribution, metabolism, and excretion (ADME) processes of drugs.
